leadf
logo-loader
RNS
viewHikma Pharmaceuticals PLC

Hikma Pharmaceutical - Block listing Interim Review

RNS Number : 8056A
Hikma Pharmaceuticals Plc
01 October 2020
 

Hikma Pharmaceuticals PLC

 

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

 

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 ordinary shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 ordinary shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

LTIP: 87,700 ordinary shares of 10 pence

 

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

LTIP: 0 ordinary shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

LTIP: 30,198 ordinary shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

LTIP: 57,502 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

MIP: 1,519,989 ordinary shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

MIP: 0 ordinary shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

MIP: 380,293 ordinary shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

MIP: 1,139,696 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

EIP: 1,102,558 ordinary shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

EIP: 0 ordinary shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

EIP: 590,134 ordinary shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

EIP: 512,424 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

LEI: 549300BNS685UXH4JI75

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRUPGUUUUPUGUG

Quick facts: Hikma Pharmaceuticals PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read